|
Synonyms: ALXN-1720 | ALXN1720 | CON-9978 | Klygefa® | TPP-2511
Compound class:
Antibody
Comment: Gefurulimab (ALXN1720) is a bispecific VHH nanobody that binds complement component C5 (in the terminal complement cascade) and serum albumin [1]. It is designed to block enzymatic cleavage of C5 (into biologically active C5a and C5b fragments), and reduce inflammation. Binding to serum albumin extends the agent's systemic half-life and therapeutic window.
|
| No information available. |
Summary of Clinical Use ![]() |
| Gefurulimab (ALXN1720) was progressed to clinical evaluations to determine immunomodulatory potential in complement-mediated diseases [2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | Phase 3 Interventional | Alexion Pharmaceuticals, Inc. | ||
| NCT06607627 | PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | Phase 3 Interventional | Alexion Pharmaceuticals, Inc. | ||